Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
IPO Year: 2020
Exchange: NASDAQ
Website: inarimedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2024 | $50.00 | Hold | Stifel |
| 9/3/2024 | $47.00 | Market Perform | Leerink Partners |
| 8/9/2024 | $68.00 | Buy | Deutsche Bank |
| 7/25/2024 | Outperform | William Blair | |
| 7/18/2024 | Buy → Hold | Needham | |
| 2/29/2024 | $85.00 → $55.00 | Overweight → Neutral | Piper Sandler |
| 1/23/2024 | $72.00 | Buy | Needham |
| 7/19/2023 | $79.00 | Outperform | Robert W. Baird |
| 10/12/2022 | $88.00 | Buy | Jefferies |
| 9/29/2022 | $85.00 | Buy | Berenberg |
10-Q - Inari Medical, Inc. (0001531048) (Filer)
8-K - Inari Medical, Inc. (0001531048) (Filer)
144 - Inari Medical, Inc. (0001531048) (Subject)
10-Q - Inari Medical, Inc. (0001531048) (Filer)
8-K - Inari Medical, Inc. (0001531048) (Filer)
8-K - Inari Medical, Inc. (0001531048) (Filer)
144 - Inari Medical, Inc. (0001531048) (Subject)
SD - Inari Medical, Inc. (0001531048) (Filer)
144 - Inari Medical, Inc. (0001531048) (Subject)
144 - Inari Medical, Inc. (0001531048) (Subject)
Stifel initiated coverage of Inari with a rating of Hold and set a new price target of $50.00
Leerink Partners initiated coverage of Inari with a rating of Market Perform and set a new price target of $47.00
Deutsche Bank initiated coverage of Inari with a rating of Buy and set a new price target of $68.00
William Blair initiated coverage of Inari with a rating of Outperform
Needham downgraded Inari from Buy to Hold
Piper Sandler downgraded Inari from Overweight to Neutral and set a new price target of $55.00 from $85.00 previously
Needham initiated coverage of Inari with a rating of Buy and set a new price target of $72.00
Robert W. Baird initiated coverage of Inari with a rating of Outperform and set a new price target of $79.00
Jefferies initiated coverage of Inari with a rating of Buy and set a new price target of $88.00
Berenberg initiated coverage of Inari with a rating of Buy and set a new price target of $85.00
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
3 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
4/A - Inari Medical, Inc. (0001531048) (Issuer)
4 - Inari Medical, Inc. (0001531048) (Issuer)
IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Financial and Recent Business Highlights Generated revenue of $153 million in Q3 of 2024, up 21% over the same quarter of last year.GAAP operating loss was $13.6 million in Q3 of 2024, compared to a $2.1 million operating income in the same quarter of last year.Non-GAAP operating loss was $0.4 million in Q3 of 2024, compared to a $4.8 million non-GAAP operating income in t
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be acc
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that Mitch Hill, Chief Financial Officer, will retire effective October 1, 2024 and will be succeeded by Kevin Strange, Inari's current SVP, Finance, Accounting, Strategy and Business Development. Mr. Hill has served as the CFO since 2019, and prior to that in various senior financial roles spanning over four decades. Mr. Strange joined Inari in 2020 as VP, Strategy and Business Development. Since 2023 he has served as the SVP, Finance, Accounting, Strate
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2024. Second Quarter Financial and Recent Business Highlights Generated revenue of $146 million in Q2 of 2024, up 23% over the same quarter last year.Commenced full commercial launch of VenaCore, Inari's latest purpose-built device for the treatment of acute and chronic DVT.Cash, cash equivalents and short-term investments were $110 million as of Q2 of 2024. "Our second quarter performance was
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be accessed by v
IRVINE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2024. First Quarter Financial and Recent Business Highlights Generated revenue of $143.2 million in Q1 of 2024, up 23.3% over the same quarter last year.GAAP operating loss was $17.2 million in Q1 of 2024, compared to a $5.3 million operating loss in the same quarter of last year.Non-GAAP operating loss was $5.6 million in Q1 of 2024, compared to a $5.3 million non-GAAP operating loss in the same qu
IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be accessed by
IRVINE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2023. Fourth Quarter Financial and Recent Business Highlights Generated revenue of $132.1 million in Q4 of 2023, up 22.6% over the same quarter last year.GAAP operating loss was $9.3 million in Q4 of 2023, compared to a $5.9 million operating loss in the same quarter of last year.Non-GAAP operating loss was $0.3 million in Q4 of 2023, compared to a $5.9 million non-GAAP operating lo
IRVINE, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2023. Third Quarter Financial and Recent Business Highlights Generated revenue of $126.4 million in Q3 of 2023, up 31.4% over the same quarter last year.Delivered net income of $3.2 million in Q3 of 2023, compared to a $10.2 million net loss in the same quarter of last year.Ended the quarter with cash and investments of $351.3 million. Announced an expansion of our patient-focused mission with a
SC 13G - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
SC 13G/A - Inari Medical, Inc. (0001531048) (Subject)
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced positive results from the prospective PEERLESS Randomized Controlled Trial (RCT) comparing FlowTriever to catheter-directed thrombolytics (CDT). The results were presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine and Co-Global Principal Investigator (PI), during the Late-Breaking Clinical Trial Session at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. In reco
IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024. Third Quarter Financial and Recent Business Highlights Generated revenue of $153 million in Q3 of 2024, up 21% over the same quarter of last year.GAAP operating loss was $13.6 million in Q3 of 2024, compared to a $2.1 million operating income in the same quarter of last year.Non-GAAP operating loss was $0.4 million in Q3 of 2024, compared to a $4.8 million non-GAAP operating income in t
ALISO VIEJO, Calif., Oct. 21, 2024 /PRNewswire/ -- Okami Medical today announced the closing of a $32.5M financing led by new investor Vensana Capital and joined by existing investors including U.S. Venture Partners, members of Okami's board of directors, and other medical device industry veterans. Okami was launched by medical device incubator Inceptus Medical, whose principals previously founded other category-defining vascular companies including Inari Medical, Sequent Medical, and MicroVention. The financing provides Okami with capital to accelerate development and commerc
IRVINE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- In recognition of World Thrombosis Day, Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced collaborative partnerships with the American Venous Forum ("AVF") and the National Blood Clot Alliance ("NBCA") on the DEFIANCE trial. This prospective, multinational, randomized controlled trial ("RCT") will evaluate and compare clinical outcomes in patients with deep vein thrombosis ("DVT") treated with Inari's ClotTriever System versus anticoagulation alone. AVF is a non-profit society dedicated to improving the
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The analyst and investor meeting will be held on Tuesday, October 29, 2024 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time. Interested parties may access the live event by visiting the Events Sec
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be acc
IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th. The PEERLESS trial is a prospective, randomized controlled trial ("RCT") comparing the outcomes of patients with int
IRVINE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences: 22nd Annual Morgan Stanley Global Healthcare ConferencePresenting on Wednesday, September 4, 2024 at 7:45 a.m. Eastern Time 2024 Wells Fargo Healthcare ConferencePresenting on Friday, September 6, 2024 at 8:00 a.m. Eastern Time A live audio webcast and replay of each presentation may be accessed on the "Investor Relations" section of the company's website at: https://www.inarim
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that Mitch Hill, Chief Financial Officer, will retire effective October 1, 2024 and will be succeeded by Kevin Strange, Inari's current SVP, Finance, Accounting, Strategy and Business Development. Mr. Hill has served as the CFO since 2019, and prior to that in various senior financial roles spanning over four decades. Mr. Strange joined Inari in 2020 as VP, Strategy and Business Development. Since 2023 he has served as the SVP, Finance, Accounting, Strate
IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2024. Second Quarter Financial and Recent Business Highlights Generated revenue of $146 million in Q2 of 2024, up 23% over the same quarter last year.Commenced full commercial launch of VenaCore, Inari's latest purpose-built device for the treatment of acute and chronic DVT.Cash, cash equivalents and short-term investments were $110 million as of Q2 of 2024. "Our second quarter performance was
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), today announced the appointment of Tim Benner as Senior Vice President of U.S. Sales and Dr. Andrew Niekamp as Vice President of Medical Affairs. Mr. Benner will be responsible for developing effective strategies across the company's multi-product sales platform and leading a high-performance commercial team to drive therapy penetration. Dr. Niekamp will be instrumental in advancing Inari's mission to improve patient care through physician education and new device development. "We are thrilled to welcome Tim to Inari. His extensive experience leading the commercial execution of disruptive healt
NEW YORK, March 25, 2024 /PRNewswire/ -- AppFolio Inc. (NASD:APPF) will replace Inari Medical Inc. (NASD:NARI) in the S&P MidCap 400, and Inari Medical will replace Callon Petroleum Co. (NYSE:CPE) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. S&P 500 constituent APA Corp. (NASD:APA) is acquiring Callon Petroleum in a transaction expected to be completed on or about that date pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition AppFolio APPF Information Technology S&P
ALISO VIEJO, Calif., Jan. 8, 2024 /PRNewswire/ -- Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced the appointment of Rhonda Robb as President and Chief Executive Officer. Rhonda is a proven medical device executive with more than 25 years of leadership and commercial experience. She most recently served as Chief Operating Officer at Cardiovascular Systems, Inc., a leader in the treatment of peripheral and coronary artery disease. Prior to Cardiovas
LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that it has entered into a definitive agreement to be acquired by Inari Medical (NASDAQ:NARI), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Under the terms of the agreement, LimFlow will receive $250 million in cash at closing and be eligible to receive up to $165 million in additional payments based on certain commercial and reimbursement milestones, for a total potential transaction value of up to $415 mill
IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the appointment of Mr. Robert Warner to its board of directors. Mr. Warner will serve as a member of the Audit Committee of the board. "We are pleased to welcome Robert as a new independent director to our board. Mr. Warner's decades of executive operating experience, including internationally, will be highly valuable to Inari as we enter the next phase of our mission to treat and transform the lives of patients suffering from venous and other diseases,"
IRVINE, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Mr. Dana G. Mead, Jr. to its board of directors. Mr. Mead will serve as a member of the Compensation Committee of the board. "We are pleased to welcome Dana as a new independent director to our board. Mr. Mead's decades of executive operating experience leading high growth med tech businesses, will be highly valuable to Inari as we enter the next phase of our mission to treat and transform the lives of patients suffering from veno
IRVINE, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the company has appointed Victor F. Tapson, M.D. as VP of Medical Affairs. Dr. Tapson has devoted his medical career to patient care, research, and teaching in pulmonary hypertension and pulmonary embolism. He has authored more than 200 peer-reviewed manuscripts and was involved in the development of the American Thoracic Society's clinical practice guidelines for the diagnosis of venous thromboembolism. "I am thrilled to be joining Inari M
IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Ms. Rebecca Chambers to its board of directors. Ms. Chambers also will serve as a member of the Audit Committee. Ms. Chambers, currently Chief Financial Officer of Outset Medical, Inc., brings more than a decade of healthcare leadership experience. Over the course of her career, Ms. Chambers has led numerous financial functions as well as served in leadership roles in investor relations for publicly traded companies in the healthcar
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, today announced the appointment of Katie Szyman to its board of directors. Szyman, currently Corporate Vice President and General Manager of Critical Care at Edwards Lifesciences, brings more than 30 years of global medtech leadership experience. With a focus on driving sustainable, high-growth revenue, Szyman has introduced to market patient-focused innovations that also drive cost efficiencies for providers. "Katie's impressive track record of ushering medical device companies through market expansion and high growth is ideally sui
William Blair analyst Margaret Andrew initiates coverage on Inari Medical (NASDAQ:NARI) with a Outperform rating.
n
Needham analyst Mike Matson downgrades Inari Medical (NASDAQ:NARI) from Buy to Hold.
Throughout the last three months, 5 analysts have evaluated Inari Medical (NASDAQ:NARI), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 1 0 0 Analysts have recently evaluated Inari Medical and provided 12-month price targets. The average target is $61.2, accompanied by a high estimate of $84.00 and a low estimate of $50.00. This current average represents a 12.3
Truist Securities analyst Richard Newitter maintains Inari Medical (NASDAQ:NARI) with a Hold and raises the price target from $47 to $60.
Canaccord Genuity analyst William Plovanic maintains Inari Medical (NASDAQ:NARI) with a Buy and lowers the price target from $75 to $55.
Wells Fargo analyst Larry Biegelsen maintains Inari Medical (NASDAQ:NARI) with a Overweight and lowers the price target from $100 to $84.
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue guidance for the second quarter. AMD guided to second-quarter revenue of $5.7 billion plus or minus $300 million and a non-GAAP gross margin of about 53% against Street estimates of $5.7 billion in second-quarter revenue. Street expectations for fiscal year 2024 are for earnings of $3.40 per share and revenue of $24.13 billion, respectively, according to data from Benzinga Pro. Advanced Micro Devices shares dipped 6.9% to $147.44 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers CytomX Th
U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday. Shares of Powell Industries, Inc. (NASDAQ:POWL) rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results. Powell Industries posted GAAP earnings of $2.75 per share, beating market estimates of $1.77 per share. The company's quarterly sales came in at $255.108 million versus expectations of $201.447 million, according to data from Benzinga Pro. Powell Industries shares jumped 23.2% to $176.16 on Wednesday. Here are some other big stocks recording gains in today's session. Rocky Brands, Inc. (NASDAQ:RCKY) shares jumped 31.6% to $3